雅努斯激酶抑制剂的使用与视网膜静脉闭塞的发展之间的关系
Ophthalmic surgery, lasers & imaging retina
|September 23, 2024
概括
这项研究发现,与瘤坏死因子 (TNF) 抑制剂相比,使用Janus激酶 (Jak) 抑制剂的免疫媒介炎症疾病 (IMID) 的患者没有视网膜静脉封闭 (RVO) 的风险增加.
科学领域:
- 眼科医生 眼科 眼科
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶 (Jak) 抑制剂与潜在的血栓栓塞风险有关.
- 对Jak抑制剂与瘤亡因子 (TNF) 抑制剂在眼睛安全方面的比较对于免疫介导性炎症性疾病 (IMIDs) 患者至关重要.
研究的目的:
- 在IMID患者中,调查Janus激酶 (Jak) 抑制剂使用与视网膜静脉封闭 (RVO) 风险之间的关联.
- 为了比较Jak抑制剂和TNF抑制剂使用者之间中视网膜静脉封闭 (CRVO) 和分支视网膜静脉封闭 (BRVO) 的发生率.
主要方法:
- 使用联邦卫生研究网络进行的回顾性非随机队列研究.
- 倾向性得分匹配的风险比率被计算为CRVO和BRVO.
- 队列包括5,249名接受Jak抑制剂治疗的患者和5,249名接受IMIDsTNF抑制剂治疗的患者.
主要成果:
- 使用Jak抑制剂与TNF抑制剂的CRVO风险比率为0.61 (95%CI:0.29,1.29).
- 与Jak抑制剂相比,TNF抑制剂的BRVO风险比为0.89 (95%CI:0.47,1.72).与Jak抑制剂相比,TNF抑制剂的BRVO风险比为0.89 (95%CI:0.47,1.72).
- 在两个治疗组之间没有观察到RVO风险的统计学上显著差异.
结论:
- 这项研究没有发现证据表明,与免疫媒介性炎症性疾病 (IMID) 患者的瘤缩因子 (TNF) 抑制剂相比,与Janus激酶 (Jak) 抑制剂使用相关的视网膜静脉封闭 (RVO) 风险增加.
- 这些发现有助于了解眼科和风湿病学中Jak抑制剂的安全性.
相关概念视频
Open Angle Glaucoma: Treatment
406
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
406
Angle Closure Glaucoma: Treatment
451
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
451
Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
Glaucoma: Overview
528
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
528
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
492
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492


